Labcorp To Acquire Select Assets of MAWD Pathology Group
Acquisition aims to provide broader access to comprehensive testing and laboratory services
for patients and physicians in Kansas City and the surrounding area
BURLINGTON, N.C., (Dec. 16, 2024) — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into an agreement with MAWD Pathology Group in Lenexa, Kansas, to acquire select assets of the independent laboratory’s clinical and women’s health testing businesses. MAWD Pathology Group will continue to provide comprehensive anatomic professional and technical pathology and related services.
When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp’s high-quality laboratory services and expanded testing capabilities in communities across Kansas City and the surrounding region.
“Labcorp is committed to building upon MAWD Pathology’s long tradition of high-quality laboratory and healthcare services,” said Bryan Vaughn, Senior Vice President of Health Systems and the Mid-America Division at Labcorp. “Through this transaction, physicians, health systems, and their patients will benefit from broader access to Labcorp’s comprehensive testing portfolio while maintaining their deep pathology relationships with MAWD Pathology.”
“As we continue to deliver on our core values of quality, service and respect in every area of our practice, we are also exploring new models to bring greater value and higher levels of care to the communities we serve,” said Dr. Samuel Caughron, President & CEO of MAWD Pathology Group. “We are excited about how our agreement with Labcorp, whose team shares our commitment to improving the health of our communities through best-in-class laboratory services, will advance the highest level of pathology and laboratory care for patients in the region.”
Subject to customary closing conditions, this transaction is anticipated to close in early 2025. Until that time, there will be no changes to operations or services.
This relationship follows other acquisitions and strategic relationships that Labcorp has finalized with a range of local and regional health systems and laboratories that have enhanced services for patients and providers.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com
Media: Kimbrel Arculeo, [email protected]; Investors: Christin O'Donnell, [email protected]